Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SUCNR1 | Q9BXA5 | 14/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | NQO2 | P16083 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | OXGR1 | Q96P68 | 2/20 | 0.43 |
| ▸ | STK17B | O94768 | 1/20 | 0.42 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.42 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3227810 | 0.97 | SUCNR1 (0.47) | SUCNR1KDM4EL3MBTL1NQO2CYP3A4 | |
| SCHEMBL6422837 | 0.93 | NQO2 (0.49) | SUCNR1KDM4EL3MBTL1NQO2CYP3A4 | |
| SCHEMBL6424985 | 0.84 | KDM4E (0.48) | KDM4EL3MBTL1NQO2CYP3A4STK17B | |
| SCHEMBL13719339 | 0.81 | SUCNR1 (0.58) | SUCNR1KDM4EOXGR1BDKRB1 | |
| SCHEMBL7014475 | 0.80 | SUCNR1 (0.54) | SUCNR1L3MBTL1OXGR1 | |
| SCHEMBL15931176 | 0.80 | KDM4E (0.40) | SUCNR1KDM4EL3MBTL1NQO2BDKRB1 | |
| SCHEMBL31085307 | 0.78 | HDAC4 (0.43) | SUCNR1KDM4EOXGR1 | |
| SCHEMBL21853216 | 0.78 | HDAC4 (0.43) | SUCNR1KDM4EOXGR1 | |
| SCHEMBL21853215 | 0.78 | HDAC4 (0.43) | SUCNR1KDM4EOXGR1 | |
| SCHEMBL18626279 | 0.78 | SUCNR1 (0.43) | SUCNR1KDM4EOXGR1BDKRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4159727-B1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | MORPHIC THERAPEUTIC INC (US) | 2026-04-08 | — | — | EP | disclosed |
| US-12497399-B2 | Fluorinated integrin antagonists | OCUTERRA THERAPEUTICS, INC. (US) | 2025-12-16 | — | — | US | disclosed |
| US-12415796-B2 | Inhibitors of (αv)(β6) integrin | MORPHIC THERAPEUTIC, INC. (US) | 2025-09-16 | — | — | US | disclosed |
| US-12286432-B2 | Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereof | OCUTERRA THERAPEUTICS, INC. (US) | 2025-04-29 | — | — | US | disclosed |
| US-12221610-B2 | RNAi agents for inhibiting expression of HIF-2 alpha (EPAS1), compositions thereof, and methods of use | Arrowhead Pharmaceuticals, Inc. (US) | 2025-02-11 | — | — | US | disclosed |
| US-20240327378-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | MORPHIC THERAPEUTIC, INC. | 2024-10-03 | — | — | US | disclosed |
| EP-4435000-A2 | INTEGRIN TARGETING LIGANDS AND USES THEREOF | Arrowhead Pharmaceuticals, Inc. (US) | 2024-09-25 | — | — | EP | disclosed |
| EP-3784269-B1 | INTEGRIN TARGETING LIGANDS AND USES THEREOF | ARROWHEAD PHARMACEUTICALS INC (US) | 2024-06-05 | — | — | EP | disclosed |
| US-20240140942-A1 | FLUORINATED INTEGRIN ANTAGONISTS | FELIQS CORPORATION (JP) | 2024-05-02 | — | — | US | disclosed |
| US-20240092775-A1 | FLUORINATED TETRAHYDRONAPHTHYRIDINYL NONANOIC ACID DERIVATIVES AND USES THEREOF | FELIQS CORPORATION (JP) | 2024-03-21 | — | — | US | disclosed |
| US-20140221410-A1 | Fluorinated 3-(2-Oxo-3-(3-Arylpropyl)Imidazolidin-1-yl)-3-Arylpropanoic Acid Derivatives | SCIFLUOR LIFE SCIENCES, LLC (US) | 2014-08-07 | — | — | US | disclosed |
| US-20120289481-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | MERCK SHARP & DOHME CORP. | 2012-11-15 | — | — | US | disclosed |
| EP-1040098-B1 | INTEGRIN RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 2005-04-27 | — | — | EP | disclosed |
| US-6784190-B2 | USEFUL FOR INHIBITING BONE RESORPTION, TREATING AND PREVENTING OSTEOPOROSIS, VASCULAR RESTENOSIS, DIABETIC RETINOPATHY, MACULAR DEGENERATION, ANGIOGENESIS, TUMOR, ATHEROSCLEROSIS, INFLAMMATION, WOUND HEALING, VIRAL DISEASEDISEASE, TUMOR | MERCK & CO., INC. | 2004-08-31 | — | — | US | disclosed |
| EP-1235828-B1 | PROCESS AND INTERMEDIATES TO A TETRAHYDRO-[1,8]-NAPHTHYRIDINE | MERCK & CO INC (US) | 2004-01-21 | — | — | EP | disclosed |
| US-6423845-B1 | CYCLIZATION A 2-AMINO-3-FORMYLPYRIDINE COMPOUND; BONE DISORDERS, OSTEOPOROSIS | MERCK & CO., INC. | 2002-07-23 | — | — | US | disclosed |
| US-20020010176-A1 | Integrin receptor antagonists | MERCK SHARP & DOHME CORP. | 2002-01-24 | — | — | US | disclosed |
| US-6297249-B1 | SUBSTITUTED 2-CARBOXYALKYLPYRIDINES | MERCK & CO., INC. | 2001-10-02 | — | — | US | disclosed |
| US-6090944-A | Alkanoic acid derivatives as αv integrin receptor antagonists | MERCK & CO., INC. (US) | 2000-07-18 | — | — | US | disclosed |
| US-6048861-A | OSTEOPOROSIS; BONE DISORDERS; CARDIOVASCULAR DISORDERS; ANTIINFLAMMATROY AGENTS; WOUND HEALING AGENTS | MERCK & CO., INC. (US) | 2000-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120289481-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | MTOR, ITGB3, ITGB4 | SUCNR1 1420/4885KDM4E 571/4885L3MBTL1 3895/4885 |
| US-20240092775-A1 | FLUORINATED TETRAHYDRONAPHTHYRIDINYL NONANOIC ACID DERIVATIVES AND USES THEREOF | FFAR3, FFAR2, FFAR1 | SUCNR1 2490/4885KDM4E 4044/4885L3MBTL1 4681/4885 |
| US-20240327378-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | ITGB6, ITGA6, ITGAV | SUCNR1 2857/4885KDM4E 3514/4885L3MBTL1 1265/4885 |
| US-20240140942-A1 | FLUORINATED INTEGRIN ANTAGONISTS | ITGB5, ITGB1, ITGA5 | SUCNR1 2379/4885KDM4E 2577/4885L3MBTL1 4764/4885 |
| US-12221610-B2 | RNAi agents for inhibiting expression of HIF-2 alpha (EPAS1), compositions thereof, and methods of use | EPAS1, HIF1AN, HIF1A | SUCNR1 564/4885KDM4E 758/4885L3MBTL1 2349/4885 |
| US-12415796-B2 | Inhibitors of (αv)(β6) integrin | ITGB6, ITGA6, ITGAV | SUCNR1 2932/4885KDM4E 3739/4885L3MBTL1 1387/4885 |
| US-20140221410-A1 | Fluorinated 3-(2-Oxo-3-(3-Arylpropyl)Imidazolidin-1-yl)-3-Arylpropanoic Acid Derivatives | ITGB3, ITGA2, ITGA1 | SUCNR1 825/4885KDM4E 4092/4885L3MBTL1 4154/4885 |
| US-12286432-B2 | Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereof | FFAR3, FFAR2, FFAR1 | SUCNR1 2490/4885KDM4E 4044/4885L3MBTL1 4681/4885 |
| US-20020010176-A1 | Integrin receptor antagonists | ITGAV, ITGB3, ADGRE5 | SUCNR1 579/4885KDM4E 2532/4885L3MBTL1 1228/4885 |
| US-12497399-B2 | Fluorinated integrin antagonists | ITGB5, ITGB1, ITGA5 | SUCNR1 2379/4885KDM4E 2577/4885L3MBTL1 4764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.